cemiplimab | Cancer Search

Details 4 Related Guidelines / Approvals

type

NCCN Guideline

nccn category

1

biomarker

biomarker

PD-L1 Expression (TPS >= 50%)

condition

condition

Non-Small Cell Lung Carcinoma

settings

settings

Advanced

settings

First line

settings

Metastatic

drugs

drug

cemiplimab

drug types

drug

immunotherapy

references

link

Non-Small Cell Lung Cancer (NCCN Guidelines) [3.2022]

source

NCCN

cemiplimab

biomarker

PD-L1 Expression (TPS >= 50%)

condition

Non-Small Cell Lung Carcinoma

disease state

Locally advanced, +1 more state

therapeutic contexts

First line

drug

cemiplimab

drug type

immunotherapy

cemiplimab

condition

Basal Cell Carcinoma

disease state

Locally advanced, +1 more state

drug

cemiplimab

drug type

immunotherapy

cemiplimab

condition

Skin Squamous Cell Carcinoma

disease state

Locally advanced, +1 more state

drug

cemiplimab

drug type

immunotherapy

cemiplimab

condition

Cervical Carcinoma

disease state

Metastatic, +1 more state

therapeutic contexts

Subsequent line

drug

cemiplimab

drug type

immunotherapy

4 therapies
Page 1 of 1